- Home
- WHF vs CMPS Comparison
WHF vs CMPS Comparison
Compare WHF & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- CMPS
- Stock Information
- Founded
- WHF 2011
- CMPS 2020
- Country
- WHF United States
- CMPS United Kingdom
- Employees
- WHF N/A
- CMPS N/A
- Industry
- WHF Finance Companies
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- CMPS Health Care
- Exchange
- WHF Nasdaq
- CMPS Nasdaq
- Market Cap
- WHF 226.2M
- CMPS 246.5M
- IPO Year
- WHF 2012
- CMPS 2020
- Fundamental
- Price
- WHF $9.31
- CMPS $3.76
- Analyst Decision
- WHF Sell
- CMPS Strong Buy
- Analyst Count
- WHF 4
- CMPS 6
- Target Price
- WHF $10.83
- CMPS $20.20
- AVG Volume (30 Days)
- WHF 68.2K
- CMPS 879.5K
- Earning Date
- WHF 05-12-2025
- CMPS 05-08-2025
- Dividend Yield
- WHF 16.54%
- CMPS N/A
- EPS Growth
- WHF N/A
- CMPS N/A
- EPS
- WHF 0.47
- CMPS N/A
- Revenue
- WHF $92,817,000.00
- CMPS N/A
- Revenue This Year
- WHF N/A
- CMPS N/A
- Revenue Next Year
- WHF N/A
- CMPS N/A
- P/E Ratio
- WHF $19.86
- CMPS N/A
- Revenue Growth
- WHF N/A
- CMPS N/A
- 52 Week Low
- WHF $8.44
- CMPS $2.49
- 52 Week High
- WHF $13.44
- CMPS $9.63
- Technical
- Relative Strength Index (RSI)
- WHF 40.70
- CMPS 54.60
- Support Level
- WHF $9.27
- CMPS $3.63
- Resistance Level
- WHF $9.68
- CMPS $4.28
- Average True Range (ATR)
- WHF 0.18
- CMPS 0.30
- MACD
- WHF -0.02
- CMPS 0.01
- Stochastic Oscillator
- WHF 5.88
- CMPS 56.90
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.